Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer Medical: Multistix Urinalysis Strips for Renal Disease Detection
August 5, 2002
- GL on Subarachnoidal Hemorrhages Prepared by Korosho Study Group
July 29, 2002
- Bayer Wants to Keep 2-3% Increase in Adalat Sales
July 29, 2002
- Public Health Research Center Initiates Clinical Study on Breast Cancer
July 29, 2002
- Kuraya Sanseido Aims at Operating Profit Ratio of 2%
July 29, 2002
- Press Seminar
July 29, 2002
- Fukujin Agrees on Prices with Only 20% of Hospitals by End of June
July 29, 2002
- Takara Bio to Develop New Gene Detection System with Nanosphere
July 29, 2002
- Taiyo Pharm Beefs Up Contract Manufacturing Business
July 29, 2002
- Roche Diagnostics: Simple Blood Glucose Determination System, Accu-Chek Active
July 29, 2002
- BUSINESS NEWS IN BRIEF
July 29, 2002
- Eiken, Sysmex Tie Up to Market Urinarysis System in China
July 29, 2002
- Major Domestic Firms Feel Cool to Pfizer's Move
July 29, 2002
- InCROM Establishes EuCROM to Handle CRO Business in Europe
July 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 29, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 29, 2002
- 4.3% of ex-Koseisho Officials Were Aware of Risk of Hepatitis Due to Fibrinogen
July 29, 2002
- WORLD NEWS IN BRIEF
July 29, 2002
- Health Minister Concerned about Delay in Domestic R&D
July 29, 2002
- Nippon Kayaku Not to Spin Off Non-Pharma Business: Mr Nakamura
July 29, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…